Abstract: A method for producing a cysteine knot protein, the method including: producing the cysteine knot protein by culturing a transformed mammalian cell containing a gene encoding the cysteine knot protein and a gene encoding an exogenous chaperone protein in a protein production medium; and collecting the produced cysteine knot protein, wherein the chaperone protein includes one or more selected from the group consisting of HSP90?, HSP90?, CDC37, HSP70, HSP40, HSP60, HSP10, HSP110, and HSP27.

Abstract: Systems, methods, and devices for implementing cognitive behavioral therapy to help a subject to manage a psychiatric or mental condition of the subject are provided. Interactive digital reality (DR) activities are provided through an interactive DR scene, each configured for a subject to practice a specific reframing technique. In some embodiments, a method also includes providing one or more additional psychotherapeutic or psychoeducational techniques. Through the practice of satisfying conditions associated with each interactive DR activity, the systems, methods, and devices help a subject to manage a psychiatric or mental condition of the subject, such as by getting better at recognizing and/or challenging an anxious thought as the thought occurs, and/or by reframing the anxious thought into more a different thought using the interactive DR scene.

Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: The present disclosure provides bicyclic pyridine derivatives. A compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein X is a oxygen atom, sulfur atom, NR, or CR?R?, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R? and R? are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R?, and R?, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.

Abstract: A system comprising a client device and a server network, the client device configured to receive a query; transmit the query; receive a populated response; and display the populated response. The server network may be configured to receive the query; tokenize the query; generate an intent-match likelihood for each of a plurality of supported question intents; classify the query based on the intent-match likelihoods; evaluate each of the intent-match likelihoods to a confidence threshold; extract, via a Named Entity Recognition model, one or more entities from the query; determine one or more entity values for each of the one or more entities; query the at least one database to incorporate intent to the one or more entities and the one or more entity values; populate a response template with the one or more entity values and one or more specifics; and store the query and the populated response.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: A display control apparatus for controlling display of a display device that a user can wear acquires speech collected by a plurality of microphones, estimates a sound-arrival direction of the acquired speech, and generates a text image corresponding to the acquired speech. The display control apparatus determines an adjustment amount of a display position of the text image on the display unit of the display device based on a detection result of at least one of an operation by the user and a state of the display device. Then, the display control apparatus displays the generated text image at a display position in the display unit, the display position being determined in accordance with the estimated sound-arrival direction and the determined adjustment amount.

Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

Abstract: A display control apparatus for controlling display of a display device acquires speech collected by a plurality of microphones and estimates a sound-arrival direction of the acquired speech. Then, the display control apparatus causes a text image corresponding to the acquired speech to be displayed in a predetermined text display area in a display unit of the display device, and causes a symbol image associated with the text image to be displayed at a display position in the display unit, the display position corresponding to the estimated sound-arrival direction.

Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergie neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Abstract: The present invention relates to an oral solid dosage form comprising N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient, which has good dissolution and storage-stability. When the oral solid dosage form is a tablet, the tablet can be prepared while inhibiting tableting troubles from low content to high content of the active ingredient.

Abstract: The present invention pertains to a drug for the treatment and/or prevention of pain, more specifically to a medicinal preparation for external use to treat and/or prevent peripheral neuropathic pain, the medicinal preparation containing as an active ingredient N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: A compound represented by formula (1-1): wherein b represents an integer of 1 to 5; and Z is a group represented by formula (Z-1), formula (Z-2), formula (Z-3), formula (Za-1), formula (Za-2), formula (Za-3), formula (Za-4) or formula (Za-5), or a salt thereof.

Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Abstract: A single-stranded antisense oligonucleotide, or a pharmaceutically acceptable salt thereof, capable of modulating expression and/or function of RPS25 gene, wherein nucleotides of the single-stranded antisense oligonucleotide are bonded to each other via a phosphate group and/or a modified phosphate group, the single-stranded antisense oligonucleotide includes a gap region, a 3? wing region bonded to a 3? end of the gap region, and a 5? wing region bonded to a 5? end of the gap region, the gap region is a deoxyribose-based nucleic acid optionally including a nucleic acid having a modified sugar moiety, each of the 3? wing region and the 5? wing region is a modified nucleotide, the single-stranded antisense oligonucleotide has a base length of 12- to 30-mer, and a base sequence of the antisense oligonucleotide is: a base sequence with a sequence identity of 90% to 100% to a base sequence complementary to at least one target region of the same base length as the antisense oligonucleotide present in the base sequ

Abstract: A sightline-position determination device includes: a sightline-position input unit to which a position of a sightline of a user is inputted; a determination region setting unit which sets a determination region; a determination unit which determines whether or not the position of the sightline inputted from the sightline-position input unit falls within the determination region; and an output unit which outputs feedback to the user when the determination unit has determined that the position of the sightline falls within the determination region.